Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Trial Identifier: QHD00012
Sponsor: Sanofi Pasteur, a Sanofi Company
Start Date: November 2019
Primary Completion Date: May 2020
Study Completion Date: May 2020
Condition: Influenza Immunisation; Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Finland Tampere, Finland, 33520